Actively Recruiting
Study of Claudin18.2-Targeted Activated Dendritic Cells and CAR-T Therapy for Adults with Advanced Pancreatic Cancer
Led by Hainan Cancer Hospital · Updated on 2026-02-18
10
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new combination treatment for patients with advanced pancreatic cancer. This early phase 1 clinical study investigates Claudin18.2-targeted activated dendritic cells DCs combined with CAR-T cell therapy. The treatment aims to activate immune cells to better target tumors by reshaping the tumor environment and helping CAR-T cells kill cancer cells more effectively. The study involves giving patients autologous dendritic cells genetically modified to target Claudin18.2 and autologous T cells engineered to do the same. This combined therapy is given as a single-arm, open-label treatment without comparison groups. The study monitors participants over two years, focusing on safety and initial effectiveness. Participants will undergo regular assessments including scans and lab tests to measure tumor response, disease control, immune changes, and survival over two years. Safety is closely monitored through tracking adverse events during this period. Patients must comply with scheduled visits, medication plans, and tests throughout the study, which runs from early 2026 to 2028.
CONDITIONS
Brief Title
Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer.
Research Team
H
HAIFENG LIN
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here